These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1223 related items for PubMed ID: 8574257

  • 21. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 22. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J.
    Int J Fertil; 1991 Aug; 36 Suppl 1():25-31. PubMed ID: 1678378
    [Abstract] [Full Text] [Related]

  • 23. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U, Lambotte R.
    Bull Mem Acad R Med Belg; 1991 Aug; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [Abstract] [Full Text] [Related]

  • 24. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 Aug; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 25. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I, Jung-Hoffmann C, Kuhl H.
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of a combined oral contraceptive pill in black Zimbabwean women.
    Kasule J, Mbizvo M, Makuyana D, Masona D.
    Cent Afr J Med; 1991 Dec; 37(12):403-9. PubMed ID: 1806254
    [Abstract] [Full Text] [Related]

  • 27. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
    Nash AL, Cornish EJ, Hain R.
    Med J Aust; 1979 Sep 22; 2(6):277-81. PubMed ID: 230411
    [Abstract] [Full Text] [Related]

  • 28. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov 22; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

  • 29. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism.
    Petersen KR, Skouby SO, Pedersen RG.
    Obstet Gynecol; 1991 Oct 22; 78(4):666-72. PubMed ID: 1833682
    [Abstract] [Full Text] [Related]

  • 30. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V.
    Contracept Fertil Sex (Paris); 1985 Jan 22; 13(1 Suppl):425-30. PubMed ID: 12280210
    [Abstract] [Full Text] [Related]

  • 31. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA.
    Am J Obstet Gynecol; 1989 May 22; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [Abstract] [Full Text] [Related]

  • 32. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O, Kuusi T, Tikkanen MJ, Viinikka L.
    J Clin Endocrinol Metab; 1987 Dec 22; 65(6):1238-42. PubMed ID: 2960690
    [Abstract] [Full Text] [Related]

  • 33. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G.
    Int J Fertil; 1989 Sep 22; 34 Suppl():31-9. PubMed ID: 2576255
    [Abstract] [Full Text] [Related]

  • 34. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J.
    Contraception; 2005 Feb 22; 71(2):111-7. PubMed ID: 15707560
    [Abstract] [Full Text] [Related]

  • 35. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
    Bonnar J, Daly L, Carroll E.
    Int J Fertil; 1987 Feb 22; 32 Suppl():21-8. PubMed ID: 2906344
    [Abstract] [Full Text] [Related]

  • 36. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN, Liew D, Ratnam SS.
    Contraception; 1989 Jan 22; 39(1):21-35. PubMed ID: 2521321
    [Abstract] [Full Text] [Related]

  • 37. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS, Kaye JA, Russmann S, Jick H.
    Contraception; 2006 Jun 22; 73(6):566-70. PubMed ID: 16730485
    [Abstract] [Full Text] [Related]

  • 38. Lipoprotein alterations from a triphasic oral contraceptive containing ethinyl estradiol and gestodene. A 12-month trial.
    Moutos DM, Zacur HA, Bachorik PS, Wallach EE.
    J Reprod Med; 1994 Sep 22; 39(9):720-4. PubMed ID: 7807486
    [Abstract] [Full Text] [Related]

  • 39. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA, Bonnar J.
    Br J Obstet Gynaecol; 1996 Mar 22; 103(3):261-7. PubMed ID: 8630312
    [Abstract] [Full Text] [Related]

  • 40. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R.
    Contraception; 1996 Mar 22; 53(3):171-6. PubMed ID: 8689882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 62.